We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Inspira Pharmaceuticals (IP) is forming a possible new therapy for COVID-19. IP asserts that its in-lab plant-based molecular formulation has killed over 95% of the SARS-CoV-2 virus. The company aims to understand whether a COVID-19 patient can safely inhale the formulation directly into their lungs as an effective treatment. IP has secured cornerstone investment from biotech angel investors and a Singaporean Venture Capitalist (VC) for its formula. IP argues that its technology has the potential for addressing other respiratory infections such as cystic fibrosis, influenza and the common cold in the coming months. The company will use the investment to develop an effective new drug, which will include further laboratory analysis, safety testing, and preparation for human trials.
days to go: Expired investment: £357,179
The first wholesaler to offer insurance products for B2B and B2C firms in the Sharing Economy. Inlet aims provide insurance for assets that have been peer-to-peer rented for the short term, or for the provision of services such as letting properties online, as these markets are not currently covered by traditional insurances. Inlet generates revenue from commissions via insurance products at the point of sale and at policy renewal. Income in the form of interest payments is also earned from customers that choose to pay via direct debit on a monthly basis, as well as from fees applied to customers who wish to amend their policies.
days to go: Expired investment: £256,514
An innovation event that displays the greatest in medical healthcare technologies within exhibitions, conferences and workshops. GIANT Health has over 2000 delegates registered, with 235 speakers and 33 exhibitors whilst being sponsored by 8 global companies. Current revenue streams consist of event ticket sales, partnership packages, stage demos, etc. Events are held across Europe, with international expansion in the next phase.
days to go: Expired investment: £62,770
Gridizen desires to change the way agencies and landlords manage their properties whilst enhancing the tenant experience. It eliminates manual methods and gives landlords and tenants a way to manage and communicate their rental property. Further, its central management team has a number of relationships within the market to build up the customer base and create a buzz about the product which other companies lack. Gridizen aspires to be the property management solution of choice for tenants and landlords. With the proceeds, it will fully develop the Property Management module, recruit an in-house technical team to oversee the development and recruit sales and marketing support.
days to go: Expired investment: £150,004
Pynk is a fintech that is doing things differently—it relies on Artificial Intelligence, crowd wisdom and expert analysis to boost social investing, allowing its users commission-free investing. Users on the Pynk platform make short term price predictions and long term forecasts on financial assets. Pynk then aggregates the data and runs it through its 'Rose' AI and experts team to give accurate trading and investment analyses. The platform has more than 27,000 users from over 180 countries. Pynk also won the 'Best AI' startups award at the AIBC Blockchain Summit in Malta. It is also a part of the London fintech accelerator programmes with National Westminster and Royal Bank of Scotland. The company will use the investment to launch a retail investor wallet in the 4th quarter of 2020, recruit £10 million Assets Under Management (AUM) by end of 2020, and build out its team across different verticals.
days to go: Expired investment: £574,550
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
Leaseum is a Business to Business (B2B) Software as a Service (SaaS) provider based in London that offers white label capital raising portals to its clients and targets alternative investment managers who deal with private equity, venture capital, real estate, hedge funds and private credit. The company claims that fundraising for alternative investments is time consuming, expensive and involves many compliance and regulatory aspects. It aims to change this by bringing together all the tools needed to raise capital such as an investor portal, a Customer Relationship Management (CRM) system, an email marketing module, e-signature facility, and investor onboarding compliances. Leaseum claims that it allows its clients to streamline their fundraising processes and convert more leads into investors via its portal. It will use 40% of the investment to strengthen its sales team, 40% to strengthen its IT team, and 20% for marketing.
days to go: Expired investment: £76,440
Ensuring an organisation's activities are compliant with key regulations. Evidology is a software program that can be easily integrated into a business's existing infrastructure. The software will check the business's data against more than 40 local and international legislation's and provide a real-time report to management that will highlight whether the business is following compliance, or not. Evidology's revenue model consists of a 3-year subscription package, in the form of a standard, or enterprise-level product. The company has tested their software within nine businesses, including HSBC. Evidology has predicted to break even as soon as 15 months, based on selling their product at a modest rate of 3 clients per month.
days to go: Expired investment: £50,003
Ablrate.com is an FCA regulated peer to peer lending platform which connects lenders with borrowers for asset-backed loans. It was launched in late 2014 and has a community of 5000 lenders who have completed £1 million+ worth of loans per month to all sizes of businesses throughout the UK.
days to go: Expired investment: £457,950
Businesses can now book meetings in pubs to discuss projects whilst enjoying food and drinks. MeetingsInn aims to satisfy the demand for companies that would prefer to hold discussions in smaller, yet livelier venues. Through their research, MeetingsInn has discovered 4,500 pubs that would be ideal locations for businesses to gather. All pubs will be audited to ensure they meet MeetingsInn's standards. MeetingsInn generates revenue from a 10% commission of all bookings confirmed, as well as pubs that wish to advertise and have premium listings on the website.  This crowdfunding round will allow MeetingsInn to list more pubs on their platform, as well as enhance their booking service to include tools and resources such as group accommodations.
days to go: Expired investment: £60,960
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph